Myelodysplastic syndrome -> bone marrow disorder
Conditions
Interventions
Protocol pg. 14, 15
- MRI T2* liver: liver iron content
- MRI T2* heart: myocardial iron content and ejection fraction
- Echocardiography: evaluation of the left ventricular diastolic function
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patients with MDS according to WHO 2001-criteria (RA, RARS, RAEB-1, RAEB-2, RCMD, RCMD-RS, MDS with isolated del(5q), MDS-U). - Patient with IPSS low-risk, intermediate-1 or intermediate-2 risk. - Untreated patients or patients treated with blood transfusions, growth factors, iron chelation therapy, the immunomodulatory drug lenalidomide or the hypomethylating agents azacitidine or decitabine. - Informed consent and of legal age at the time of obtaining informed consent (*18yrs).
Exclusion criteria
Exclusion criteria: - Patients with previous intensive anti-leukemic therapy (intensive chemotherapy and/or stem cell transplantation). - Patients with secondary or therapy-related AML and MDS after chemotherapy for a malignancy or radiotherapy. - Patients with IPSS high risk MDS. - Patients with a contraindication for MRI: Metal body parts, internal defibrillator, pacemaker, neurostimulator, bladder stimulator, insulin pump, cochlear implant, claustrophobia or another reason that prohibits MRI evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum iron, serum ferritin, transferrin saturation level, hepcidin, GDF15 and sTfR. Iron overload as assessed by MRI T2* heart and liver and left ventricular function by echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
Netherlands
Outcome results
None listed